Skip to Main Content

And so, another working week will soon draw to a close. And what a week it was. But as our savta would always remind us, “The only constant is change.” So let us turn to daydreaming about our weekend plans. Our agenda is filling up quickly. Besides raking leaves and listening to Leonard Cohen, we will attend nuptials for a favorite relative. But what about you? You could enjoy the gorgeous autumn weather. Reach out to someone special. Or simply plan the rest of your life. The possibilities are endless. Well, whatever you do, have a grand time, but be safe. Enjoy and see you soon …

Valeant Pharmaceuticals may change its name in order to break with its scandalous past, Reuters tells us. Board member and leading investor William Ackman says the beleaguered drug maker, weighed down by probes into accounting and pricing practices, has become a poster child for high drug prices and a name change may help boost its sullied reputation.

A UK appeals court ruled that the National Health Service in England has the legal power to pay for an HIV pill to prevent infection, PharmaTimes writes. The decision was a victory for AIDS campaigners who have been calling for widespread use of PrEP, or pre-exposure prophylaxis, which can lower the risk of contracting the virus during sex by more than 90 percent, according to studies. The NHS argued it could not be in a position to fund a preventive service.


Politicians from several countries are hoping to convince the European Medicines Agency to relocate once Brexit is complete, Bloomberg News tells us. Sweden, France, Denmark, Hungary, and Bulgaria are among those making pitches. Once the UK leaves the European Union, EU officials may look to relocate the agency elsewhere within the 28-nation bloc.

The US Food and Drug Administration cleared Adaptimmune to start a trial of its liposarcoma therapy, lifting a clinical hold imposed in August when the agency asked for more manufacturing data.


The FDA approved Bristol-Myers Squibb’s Opdivo as the first immunotherapy for head and neck cancer, which is the seventh most common cancer globally, causing up to 600,000 new cases a year, PharmaTimes writes.

Teleflex Medical recalled devices used to deliver rescue therapies to people who have overdosed on opioids, following complaints of mechanism failure, InPharma Technologist reports.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended renewing conditional marketing authorization of PTC Therapeutics’s Translarna treatment for Duchenne muscular dystrophy.

Novovax will lay off 30 percent of its workforce following a failed Phase 3 clinical trial of its lead respiratory syncytial virus vaccine candidate for older adults, the Washington Business Journal says.

  • A ‘name change’ for Valeant – of course, what a great solution to their… issues. Why not ‘Biovail?’ No need to search if it’s taken, although ‘Bio-travail’ might be a better fit?

    • Looks like indeed Papa’s got a brand new bag. Step 1) you rebrand the company, Step 2) you raise drug prices to pay for the rebranding, 3) Step 3 you can get away with jacking up prices AGAIN. WHY? Because you are like a brand new company. The name Valeant has been obliterated from people’s memory banks like a scene from “The Outer Limits”. Now you are just another drug company charging outrageously high prices with no track record. Ingenious!

Comments are closed.